Osaic Holdings Inc. Grows Holdings in Guardant Health, Inc. $GH

Osaic Holdings Inc. increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 118.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,561 shares of the company’s stock after acquiring an additional 16,039 shares during the quarter. Osaic Holdings Inc.’s holdings in Guardant Health were worth $1,538,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Signaturefd LLC lifted its position in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the last quarter. IFP Advisors Inc lifted its holdings in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of Guardant Health by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock worth $1,106,000 after purchasing an additional 348 shares during the last quarter. F m Investments LLC boosted its holdings in shares of Guardant Health by 1.2% during the second quarter. F m Investments LLC now owns 39,099 shares of the company’s stock valued at $2,035,000 after acquiring an additional 471 shares during the period. Finally, Allworth Financial LP boosted its stake in Guardant Health by 358.4% during the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after purchasing an additional 552 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Down 0.8%

NASDAQ GH opened at $100.60 on Wednesday. The stock has a market capitalization of $12.68 billion, a PE ratio of -31.34 and a beta of 1.58. Guardant Health, Inc. has a 12-month low of $30.15 and a 12-month high of $112.43. The company has a 50 day moving average price of $97.32 and a two-hundred day moving average price of $70.30.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter last year, the business posted ($0.88) EPS. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on GH shares. William Blair restated an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target for the company in a report on Thursday, September 25th. BTIG Research increased their price objective on Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Morgan Stanley raised their target price on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Finally, Citigroup lifted their price target on Guardant Health from $100.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Twenty-three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $96.71.

Insider Activity at Guardant Health

In related news, CFO Michael Brian Bell sold 80,362 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $103.14, for a total value of $8,288,536.68. Following the completion of the sale, the chief financial officer directly owned 28,052 shares in the company, valued at approximately $2,893,283.28. The trade was a 74.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the sale, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. The trade was a 37.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 426,663 shares of company stock valued at $44,508,069. Insiders own 6.10% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.